# Fcer1g and St3gal1: Macrophage-associated angiogenesis biomarkers and therapeutic targets in sepsis-induced acute lung injury

**Authors:** Lu Liu, Peiyao Luo, Man Wang, Shihuan Yu, Jinling Xiao

PMC · DOI: 10.1371/journal.pone.0343449 · PLOS One · 2026-02-27

## TL;DR

This study identifies two genes, Fcer1g and St3gal1, as potential biomarkers and therapeutic targets for sepsis-induced lung injury by analyzing their role in macrophage-driven angiogenesis.

## Contribution

The study introduces Fcer1g and St3gal1 as novel macrophage-associated biomarkers for sepsis-induced acute lung injury with strong diagnostic accuracy.

## Key findings

- Fcer1g and St3gal1 are significantly upregulated in sepsis-induced lung injury with high diagnostic accuracy (AUC > 0.85).
- These genes are strongly associated with macrophage infiltration, particularly M2-polarized subsets.
- In mouse models, these genes mediate macrophage-endothelial interactions via glycoimmune signaling pathways.

## Abstract

Acute lung injury (ALI) involves the release of growth factors and inflammatory mediators from damaged pulmonary tissues, fostering endothelial cell proliferation, migration, and vascular lumen formation, thereby driving pathological angiogenesis. Macrophages contribute to angiogenesis and vascular homeostasis, but their dysregulation in pathological states worsens vascular dysfunction. This study aims to identify macrophage-associated angiogenesis-related genes as novel diagnostic biomarkers and therapeutic targets for sepsis-associated ALI (SALI).

Transcriptomic datasets from the GEO database were analyzed using differential expression profiling and weighted gene co-expression network analysis (WGCNA) to identify candidate genes. These candidates were compared with macrophage- and angiogenesis-related gene sets from GENECARDS for functional prioritization. Three machine learning algorithms (LASSO regression, random forest, and SVM) were employed to refine predictive biomarkers, followed by immune infiltration analysis (via CIBERSORT) to assess correlations with immune subsets. Single-cell RNA sequencing and RT-PCR were used for spatial validation of gene expression.

Two macrophage-associated angiogenesis-related genes, Fcer1g (FCER1G) and St3gal1 (ST3GAL1), were identified as key biomarkers. Both genes showed significant upregulation in the training cohort (p < 0.001) and independent validation sets (p < 0.05), with robust diagnostic accuracy (AUC > 0.85). Immune correlation analysis indicated strong positive associations with macrophage infiltration (p < 0.01), particularly M2-polarized subsets. scRNA-seq confirmed their predominant expression in macrophage clusters, with increased activity in SALI tissues (log2FC > 2.0, p < 0.001).

In mouse in vivo studies, Fcer1g and St3gal1 were shown to precisely mediate intricate macrophage-endothelial cell interactions via glycoimmune signaling pathways at the molecular level. This interaction finely modulates endothelial cell activation and drives angiogenic remodeling, critically impacting SALI progression. Given the physiological and pathological parallels between mice and humans, our findings offer a theoretical underpinning for subsequent human – oriented research. Moving forward, efforts should focus on verifying the expression patterns, action mechanisms, and diagnostic/therapeutic potential of these genes in relation to human SALI – associated signatures.

## Linked entities

- **Genes:** FCER1G (Fc epsilon receptor Ig) [NCBI Gene 2207], ST3GAL1 (ST3 beta-galactoside alpha-2,3-sialyltransferase 1) [NCBI Gene 6482]
- **Diseases:** acute lung injury (MONDO:0006502)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** St3gal1 (ST3 beta-galactoside alpha-2,3-sialyltransferase 1) [NCBI Gene 20442] {aka 5330418N22Rik, ST3GalI, Siat4, Siat4a, St3gal-1}, NCR1 (natural cytotoxicity triggering receptor 1) [NCBI Gene 9437] {aka CD335, LY94, NK-p46, NKP46}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, IGKV2-24 (immunoglobulin kappa variable 2-24) [NCBI Gene 28923] {aka A23, IGKV224}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, IL6R (interleukin 6 receptor) [NCBI Gene 3570] {aka CD126, HIES5, IL-1Ra, IL-6R, IL-6R-1, IL-6RA}, IL1R1 (interleukin 1 receptor type 1) [NCBI Gene 3554] {aka CD121A, CRMO3, D2S1473, IL-1R-alpha, IL-1RT1, IL1R}, SMAD2 (SMAD family member 2) [NCBI Gene 4087] {aka CHTD8, JV18, JV18-1, LDS6, MADH2, MADR2}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, FCGR3A (Fc gamma receptor IIIa) [NCBI Gene 2214] {aka CD16-II, CD16A, FCG3, FCGR3, FCRIIIA, FcGRIIIA}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, FCER1G (Fc epsilon receptor Ig) [NCBI Gene 2207] {aka FCRG}, TNFRSF1A (TNF receptor superfamily member 1A) [NCBI Gene 7132] {aka CD120a, FPF, TBP1, TNF-R, TNF-R-I, TNF-R55}, SMAD3 (SMAD family member 3) [NCBI Gene 4088] {aka HSPC193, HsT17436, JV15-2, LDS1C, LDS3, MADH3}, ST3GAL1 (ST3 beta-galactoside alpha-2,3-sialyltransferase 1) [NCBI Gene 6482] {aka Gal-NAc6S, SIAT4A, SIATFL, ST3GalA, ST3GalA.1, ST3GalIA}, Fcer1g (Fc receptor, IgE, high affinity I, gamma polypeptide) [NCBI Gene 14127] {aka CD23, FcR-gamma, FcR[g], FcRgamma, Fce1g, FcepsilonRI}
- **Diseases:** fibrotic diseases (MESH:D004194), neurological conditions (MESH:D019636), pulmonary infection (MESH:D012141), inflammation (MESH:D007249), fibrosis (MESH:D005355), Acute Lung Injury (MESH:D055371), liver and kidney fibrosis (MESH:D008103), asthma (MESH:D001249), alveolar edema (MESH:D004487), acute pancreatitis (MESH:D010195), lung injury (MESH:D055370), tumor (MESH:D009369), pulmonary inflammatory (MESH:D016726), pulmonary inflammation (MESH:D011014), acute respiratory failure (MESH:D012131), autoimmune diseases (MESH:D001327), hypoxemia (MESH:D000860), ARDS (MESH:D012128), tumor metastasis (MESH:D009362), vascular dysfunction (MESH:D002561), cardiovascular disorders (MESH:D002318), coagulation disorders (MESH:D001778), renal diseases (MESH:D007674), ccRCC (MESH:D002292), Sepsis (MESH:D018805), rhinosinusitis (MESH:D000092562), necrotic (MESH:D009336)
- **Chemicals:** oxygen (MESH:D010100), sialic acid (MESH:D019158), streptomycin (MESH:D013307), CMP - sialic acid (MESH:D003569), galactose (MESH:D005690), penicillin (MESH:D010406), DMEM (-), LPS (MESH:D008070), carbon dioxide (MESH:D002245), PBS (MESH:D007854)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** RAW264.7 — Mus musculus (Mouse), Mouse leukemia, Cancer cell line (CVCL_0493)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12948084/full.md

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12948084/full.md

## References

57 references — full list in the complete paper: https://tomesphere.com/paper/PMC12948084/full.md

---
Source: https://tomesphere.com/paper/PMC12948084